Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

ABP 980

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Introduction Although the human epidermal growth factor receptor 2 (HER2) blocker trastuzumab is generally well tolerated… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
2019
2019
BackgroundABP 980 has been developed as a biosimilar to Herceptin® (trastuzumab). Comprehensive analytical characterization… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Review
2019
Review
2019
ABP 980 was developed as a biosimilar to trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Review
2018
Review
2018
BACKGROUND ABP 980 (Amgen Inc, Thousand Oaks, CA, USA) is a biosimilar of trastuzumab, with analytical, functional, and… Expand
Review
2018
Review
2018
ABP 980 (KANJINTI™) is a biosimilar of the reference anti-HER2 antibody trastuzumab. In the EU, ABP 980 is approved for use in… Expand
  • table 1
  • figure 1
  • table 2
Review
2018
Review
2018
ABSTRACT Introduction: Approval of the HER2-targeted antibody trastuzumab dramatically improved outcomes for patients with HER2… Expand
2018
2018
Background: Analytical, functional, and pharmacokinetic similarity between ABP 980 and trastuzumab (TRAS) has been demonstrated… Expand
2018
2018
Background: Analytical, functional, and pharmacokinetic similarity between the proposed biosimilar ABP 980 and trastuzumab (TRAS… Expand
2017
2017
PurposeThis study compared the pharmacokinetic (PK) profiles of the proposed biosimilar ABP 980 and trastuzumab in healthy males… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
2016
2016
Background: ABP 980 is being developed as a biosimilar to trastuzumab, a monoclonal antibody (mAb) that binds human epidermal… Expand